Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor

被引：0
|
作者：
Wylie, Natasha S. [1 ]
Sokumbi, Olayemi [2 ]
Starr, Jason S. [1 ]
机构：
[1] Mayo Clin, Div Hematol & Med Oncol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA
[2] Mayo Clin, Dept Dermatol, Jacksonville, FL 32224 USA
来源：
JAMA ONCOLOGY | 2021年 / 7卷 / 12期
关键词：
D O I：
10.1001/jamaoncol.2021.5578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1891 / 1892
页数：2
相关论文
共 50 条
  • [31] Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium
    Chen, Pei-Yu
    Qin, Lingfeng
    Tellides, George
    Simons, Michael
    SCIENCE SIGNALING, 2014, 7 (344) : ra90
  • [32] Fibroblast growth factor receptor inhibitor-induced hyperphosphatemia: Lessons for the nephrologist
    Attieh, Rose Mary
    Upadrista, Pratap
    Levy, Anna T.
    Jhaveri, Kenar D.
    CLINICAL NEPHROLOGY, 2024, 103 (01) : 12 - 18
  • [33] Antiangiogenic Activity of Alofanib, an Allosteric Inhibitor of Fibroblast Growth Factor Receptor 2
    Khochenkov, D. A.
    Solomko, E. Sch.
    Peretolchina, N. M.
    Ryabaya, O. O.
    Stepanova, E. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2015, 160 (01) : 84 - 87
  • [34] Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
    Sarkisian, Saro
    McIntosh, Alyson
    Nair, Suresh
    Shoushtari, Alexander N.
    Callahan, Margaret
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [35] ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA)
    Mazzaferro, V.
    Shaib, W.
    Rimassa, L.
    Harris, W.
    Personeni, N.
    El-Rayes, B.
    Tolcher, A.
    Hall, T.
    Wang, Y.
    Schwartz, B.
    Kazakin, J.
    Busset, M. Droz Dit
    Cotsoglou, C.
    Papadopoulos, K.
    ANNALS OF ONCOLOGY, 2016, 27 : 109 - 109
  • [36] Fibroblast Growth Factor Receptor Inhibitors
    Kumar, Suneel B. V. S.
    Narasu, Lakshmi
    Gundla, Rambabu
    Dayam, Raveendra
    Sarma, J. A. R. P.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (04) : 687 - 701
  • [37] Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations
    Lindley, Anouk
    Prager, Gerald
    Bitzer, Michael
    Burn, Timothy C.
    Lihou, Christine F.
    Croft, Elisabeth
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 847 - 855
  • [38] Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors
    Casalino, S.
    Gerdes, C.
    Saborowski, A.
    Quinzii, A.
    Zecchetto, C.
    Sordo, A.
    Messineo, L.
    Leta, L. C.
    Lucin, E.
    Mendo, L.
    Pietrobono, S.
    Vogel, A.
    Melisi, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S128 - S129
  • [39] Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma
    Tsujie, Masanori
    Iwai, Tomohisa
    Kubo, Shoji
    Ura, Takashi
    Hatano, Etsuro
    Sakai, Daisuke
    Takeda, Yutaka
    Kaibori, Masaki
    Kobayashi, Tomoe
    Katanuma, Akio
    Katayose, Yu
    Fukase, Koji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (06) : 911 - 917
  • [40] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
    Arai, Yasuhito
    Totoki, Yasushi
    Hosoda, Fumie
    Shirota, Tomoki
    Hama, Natsuko
    Nakamura, Hiromi
    Ojima, Hidenori
    Furuta, Koh
    Shimada, Kazuaki
    Okusaka, Takuji
    Kosuge, Tomoo
    Shibata, Tatsuhiro
    HEPATOLOGY, 2014, 59 (04) : 1427 - 1434
12345